Year: 2017
Type: review
Abstract: Fibrosis is defined as excess deposition of extracellular matrix, resulting in tissue scarring and organ dysfunction. It is estimated that 45% of deaths in the developed world are due to fibrosis-induced organ failure. Despite the well-accepted role of fibrosis in the pathogenesis of numerous diseases, there are only two US Food and Drug Administration-approved anti-fibrotic therapies, both of which are currently restricted to the treatment of pulmonary fibrosis. Thus, organ fibrosis represents a massive unmet medical need. Here, we review recent findings suggesting that an epigenetic regulatory protein, BRD4, is a nodal effector of organ fibrosis, and we highlight the potential of small-molecule BRD4 inhibitors for the treatment of diverse fibrotic diseases.
Source: F1000Research
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,350
Awards: KLF15 and Transcriptional Control of Muscle Metabolism, G2455107118, Role of BET proteins in cardiac remodeling, Regulation of Cardiac Signaling by Class I Histone Deacetylases, Post Graduate Studies in Cardiovascular Research, Epigenetic Readers as Downstream Effectors of Beta1-Adrenergic Receptor Signaling in HFrEF, Regulation of Chromatin Signaling in Heart Failure by the BRD4 Bromodomain Protein.
OpenAlex ID: W2727043747
